Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02983461 · ClinicalTrials.gov registry record · Phase 1

Use of Sildenafil for Treatment of Urinary Incontinence

A Phase 1 study of Urinary Incontinence, sponsored by The University of Texas Medical Branch, Galveston.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT02983461 is a Phase 1 study of Urinary Incontinence that is active but no longer recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 24 participants, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02983461, a Phase 1 study of Urinary Incontinence, is active but no longer recruiting, sponsored by The University of Texas Medical Branch, Galveston.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The investigators goal is to develop medical treatments for stress/mixed urinary incontinence. Sildenafil has been shown to improve blood flow as well as muscle mass and strength and to decrease muscle fatigue. The investigators believe that it will improve muscular atrophy in the pelvic floor, thus improving symptoms of urinary incontinence related to pelvic floor dysfunction.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Sildenafil

Study Locations (1)

Texas

  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2017-03-10
Est. Completion 2027-07
Phase Phase 1

What the Registry Record Tells You About NCT02983461

The ClinicalTrials.gov registry entry for NCT02983461 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (91% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02983461 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02983461 about?

NCT02983461 is a clinical study titled "Use of Sildenafil for Treatment of Urinary Incontinence". The investigators goal is to develop medical treatments for stress/mixed urinary incontinence. Sildenafil has been shown to improve blood flow as well as muscle mass and strength and to decrease muscle fatigue. The investigators believe that it will improve muscular atrophy in the pelvic floor, thus...

What is the current status of trial NCT02983461?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-03-10. Estimated completion is 2027-07.

What conditions does trial NCT02983461 study?

This clinical trial studies the following conditions: Urinary Incontinence.

What interventions are being tested in trial NCT02983461?

The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG).

Who is sponsoring clinical trial NCT02983461?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02983461 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.